Nyxoah (NASDAQ:NYXH) vs. Establishment Labs (NASDAQ:ESTA) Critical Survey

Establishment Labs (NASDAQ:ESTA) and Nyxoah (NASDAQ:NYXH) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for Establishment Labs and Nyxoah, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1	0	8	0	2.78
Nyxoah	1	1	2	0	2.25

Establishment Labs presently has a consensus price target of $100.25, suggesting a potential upside of 33.81%. Nyxoah has a consensus price target of $4.26, suggesting a potential upside of 182.25%. Given Nyxoah’s higher possible upside, analysts clearly believe Nyxoah is more favorable than Establishment Labs.

Valuation and Earnings

This table compares Establishment Labs and Nyxoah”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08 million	10.58	-$51.06 million	($1.31)	-57.19
Nyxoah	$21.66 million	2.70	-$101.92 million	($2.52)	-0.60

Establishment Labs has higher revenue and earnings than Nyxoah. Establishment Labs is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Establishment Labs and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-15.82%	-196.69%	-10.73%
Nyxoah	-443.16%	-178.90%	-81.83%

Volatility and Risk

Establishment Labs has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Institutional and Insider Ownership

72.9% of Establishment Labs shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Establishment Labs beats Nyxoah on 9 of the 14 factors compared between the two stocks.

About Establishment Labs

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.